Literature DB >> 25593802

Post-kala-Azar dermal leishmaniasis: A diagnostic dilemma in a nonendemic area.

Prachi Bhandare1, Pankaj Shukla1, Mayur Bhobe1, Varadraj V Pai1.   

Abstract

Entities:  

Year:  2014        PMID： 25593802      PMCID： PMC4290175          DOI： 10.4103/2229-5178.146190

Source DB:  PubMed          Journal:  Indian Dermatol Online J        ISSN： 2229-5178


× No keyword cloud information.
  12 in total

1.  Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.

Authors:  Vidya Nand Rabi Das; Alok Ranjan; Krishna Pandey; Dharmendra Singh; Neena Verma; Sushmita Das; Chandra S Lal; Naresh K Sinha; Rakesh B Verma; Niyamat A Siddiqui; Pradeep Das
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

Review 2.  PKDL--a drug related phenomenon?

Authors:  Simon L Croft
Journal:  Indian J Med Res       Date:  2008-07       Impact factor: 2.375

Review 3.  Recent advances in post-kala-azar dermal leishmaniasis.

Authors:  Dinesh Mondal; Md Gulam Musawwir Khan
Journal:  Curr Opin Infect Dis       Date:  2011-10       Impact factor: 4.915

4.  Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.

Authors:  C P Thakur; Amit Kumar; Gaurab Mitra; Shabnam Thakur; P K Sinha; P Das; S K Bhattacharya; Arun Sinha
Journal:  Indian J Med Res       Date:  2008-07       Impact factor: 2.375

5.  Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis.

Authors:  Sudipto Ganguly; Nilay Kanti Das; Moumita Panja; Shekhar Pal; Dolanchampa Modak; Mehebubar Rahaman; Sudeshna Mallik; Subhashis Kamal Guha; Netai Pramanik; Ramapada Goswami; Joyashree Nath Barbhuiya; Bibhuti Saha; Mitali Chatterjee
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

6.  IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.

Authors:  Samiran Saha; Smriti Mondal; Rajesh Ravindran; Swati Bhowmick; Dolanchampa Modak; Sudeshna Mallick; Mehboobar Rahman; Sourjya Kar; Ramaprasad Goswami; Subhasis Kamal Guha; Netai Pramanik; Bibhuti Saha; Nahid Ali
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

7.  Injectable paromomycin for Visceral leishmaniasis in India.

Authors:  Shyam Sundar; T K Jha; Chandreshwar P Thakur; Prabhat K Sinha; Sujit K Bhattacharya
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

8.  Post-kala-azar dermal leishmaniasis developing in miltefosine-treated visceral leishmaniasis.

Authors:  Sankha Koley; Rajesh Kumar Mandal; Sanjiv Choudhary; Arghya Bandyopadhyay
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

9.  Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.

Authors:  Sakib Burza; Prabhat Kumar Sinha; Raman Mahajan; Marta González Sanz; María Angeles Lima; Gaurab Mitra; Neena Verma; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-01-02

10.  Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients.

Authors:  Eltahir Awad Gasim Khalil; Selma Abdelmoneim Khidir; Ahmed Mudawi Musa; Brema Younis Musa; Mona Elfaki Eltahir Elfaki; Abdelgadir Mohamed Yousif Elkadaru; Edward Zijlstra; Ahmed Mohamed El-Hassan
Journal:  J Trop Med       Date:  2013-03-24
View more
  1 in total

1.  Histopathology of Post Kala-azar Dermal Leishmaniasis.

Authors:  V Ramesh; M Ramam
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.